March 21, 2024Open Access

The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Of various human epidermal growth factor receptor (HER) inhibitors, only the anti-HER2 monoclonal antibody (mAb) Herceptin/trastuzumab and the antibody-drug conjugate trastuzumab deruxtecan (T-Dxd) has been approved for the treatment of patients with stomach cancer. However, the duration of response may be short in many patients, with tumor heterogeneity being one contributing factor.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Al-Janaby et al. (Thu,) studied this question.

synapsesocial.com/papers/68e7307cb6db6435876a9894 https://doi.org/https://doi.org/10.14740/wjon1769

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar

Ver artículo completo